Prevalence and Clinical Determinants of Optimized Pharmacological Therapy in Heart Failure with Reduced Ejection Fraction
Authors:
- Anderson Oliveira EstevanAEAnderson Oliveira Estevan
- Ana Luísa Guedes de Franca e SilvaASAna Luísa Guedes de Franca e Silva
- Salvador RassiSRSalvador Rassi
- Aguinaldo Figueiredo de FreitasAFAguinaldo Figueiredo de Freitas
- Salvador RassiSRSalvador Rassi
- 31 December 2025
- journal article
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 5 (4)
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Neprilysin Inhibitors in Heart FailureJACC: Basic To Translational Science, 2022
- Optimizing Foundational Therapies in Patients With HFrEFJACC: Basic To Translational Science, 2022
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the USJAMA Network Open, 2021
- Universal Definition and Classification of Heart FailureJournal of Cardiac Failure, 2021
- Heart Failure With Reduced Ejection FractionJAMA, 2020
- Guideline-Directed Medical Therapy for Heart Failure does not Exist: A Non-Judgmental Framework for Describing the Level of Adherence to Evidence-Based Drug Treatments for Patients with a Reduced Ejection FractionEuropean Journal of Heart Failure, 2020
- Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure RegistryEuropean Journal of Heart Failure, 2018
- The Epidemiology, Clinical Manifestations, and Management of Chagas Heart DiseaseClinical Cardiology, 2015
- Heart failure and COPD: Time to SHIFT?International Journal of Cardiology, 2014
- Potential impact of optimal implementation of evidence-based heart failure therapies on mortalityAmerican Heart Journal, 2011